Adma Biologics (ADMA) EBIT Margin (2011 - 2025)
Adma Biologics (ADMA) posted EBIT Margin of 45.09% for Q4 2025, up 18.65% on a QoQ basis from 38.01% in Q3 2025, and up 1249.0% year-over-year from 3.34% in Q4 2024.
Adma Biologics (ADMA) EBIT Margin (2011 - 2025) Analysis & Trends
Adma Biologics' EBIT Margin history runs 13 years deep, the most recent figure standing at 45.09% for Q4 2025.
- Quarterly EBIT Margin rose 1249.0% year-over-year to 45.09% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 37.52% (up 493.0% YoY) and the FY2025 annual result came in at 37.53%, up 493.0% from the prior year.
- EBIT Margin was 45.09% for Q4 2025 at Adma Biologics, up from 38.01% in the prior quarter.
- Across five years, EBIT Margin topped out at 45.09% in Q4 2025 and bottomed at 94.49% in Q1 2021.
- A 5-year average of 3.56% and a median of 3.55% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2021 — EBIT Margin surged 13250 bps — and 2025, when it tumbled 149 bps.
- Adma Biologics' EBIT Margin stood at 23.98% in 2021, then surged by 49 bps to 12.12% in 2022, then jumped by 259 bps to 19.26% in 2023, then surged by 69 bps to 32.6% in 2024, then surged by 38 bps to 45.09% in 2025.
- Business Quant data shows ADMA's EBIT Margin at 45.09% in Q4 2025, 38.01% in Q3 2025, and 35.08% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Adma Biologics | 1.99 Bn | 1.91 Bn | 88.82 Mn | 45.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45.09% |
| Sep 30, 2025 | 38.01% |
| Jun 30, 2025 | 35.08% |
| Mar 31, 2025 | 30.38% |
| Dec 31, 2024 | 32.60% |
| Sep 30, 2024 | 33.08% |
| Jun 30, 2024 | 36.57% |
| Mar 31, 2024 | 26.65% |
| Dec 31, 2023 | 19.26% |
| Sep 30, 2023 | 7.90% |
| Jun 30, 2023 | -0.79% |
| Mar 31, 2023 | -1.43% |
| Dec 31, 2022 | -12.12% |
| Sep 30, 2022 | -22.67% |
| Jun 30, 2022 | -12.23% |
| Mar 31, 2022 | -50.91% |
| Dec 31, 2021 | -23.98% |
| Sep 30, 2021 | -69.81% |
| Jun 30, 2021 | -87.38% |
| Mar 31, 2021 | -94.49% |